COVID Vaccine Trials May Need Active Comparators Once Adequate Supply Reached, CBER’s Marks Says

 
• By Sarah Karlin-Smith
CBER's Peter Marks is interviewed in his basement for the FDA/CMS Summit 2020. (screenshot)
CBER Director Peter Marks speaks at the FDA-CMS Summit • Source: Informa's FDA-CMS Summit

More from Vaccines

More from Pink Sheet